Clinical study with cladribine completed

We have succesfully completed phase I study for female patients suffering from relapsing multiple sclerosis.

The aim of the study was to examine the effect of cladribine used in the treatment of relapsing multiple sclerosis on an oral contraceptive containing ethinyl estradiol and levonorgestrel.

Cladribine is a synthetic purine nucleoside that acts as an antineoplastic agent with immunosuppressive effects. Cladribine differs structurally from deoxyadenosine only by the presence of a chlorine atom at position 2 of the purine ring, which results in resistance to enzymatic degradation by adenosine deaminase.

Go back

News

Christmas wishes

To all our Sponsors, partners, subcontractors and co-workers we would like to wish joyful Christmas and a Happy New Year!

Read more …

Participation in NCBiR project

As a Clinical Site we have won a tender for an innovative 1st phase project co-funded by NCBiR.

Read more …

GMP Specialist

Ms Dorota Osińska, M.Sc., Pharmacist, QP and experienced auditor, joined BioResearch and started GMP certification process.

Read more …

New Clinical Site

We have moved to our new Clinical Site, located in Kajetany, near Warsaw, where 1st phase, BQ and BA studies will be conducted.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲